Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab + Chemotherapy in Advanced Urothelial Carcinoma
NCT05738161Phase 1Withdrawn
- Sponsor
- Insel Gruppe
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of magrolimab in urothelial carcinoma (UC), sponsored by Insel Gruppe. Primary endpoints: Dose Limiting Toxicity in Run-in Phase and Proportion of participants with any AEs of severity grade 3 or higher up to 6 months. Planned start Jun 2023; status: withdrawn.
02
Drugs
magrolimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05738161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05738161.